US life sciences M&A is showing strong vitals. Dealmaking is regaining momentum after a period of recalibration following the pandemic, and industry leaders are increasingly turning to transactions to maintain a competitive edge. Several converging factors are accelerating this surge in activity. AI-fueled innovation continues to drive change and unlock new opportunities, while strong corporate balance sheets and a return of sponsor-led activity are providing the financial means to execute large-scale transactions. Likewise, a looming patent expiration cliff and the anticipated easing of interest rates are also reinforcing a strong case for M&A.
Read the full article: Healthy Returns: US Life Sciences M&A on Track for a Banner Year //
Source: https://www.lexology.com/library/detail.aspx?g=3a33ce8d-cf6d-4f64-b4d3-3bed36cba854